Dalifa Ramadhani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Dalifa Ramadhani has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Amirah Mohd Gazzali
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia
1 shared publication - Muchtaridi Muchtaridi
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
1 shared publication - Rani Maharani
Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran
1 shared publication
Latest Publications
- Open Access
Cyclic Peptides for the Treatment of Cancers: A Review
Cyclic peptides have been widely reported to have therapeutic abilities in the treatment of cancer. This has been proven through in vitro and in vivo studies against breast, lung, liver, colon, and prostate cancers, among others. The multitude of data available in the literature supports the potential of cyclic peptides as anticancer agents. This review summarizes the findings from previously reported studies and discusses the different cyclic peptide compounds, the sources, and their modes of action as anticancer agents. The prospects and future of cyclic peptides will also be described to give an overview on the direction of cyclic peptide development for clinical applications.
Open AccessCyclic Peptides for the Treatment of Cancers: A Review
Cyclic peptides have been widely reported to have therapeutic abilities in the treatment of cancer. This has been proven through in vitro and in vivo studies against breast, lung, liver, colon, and prostate cancers, among others. The multitude of data available in the literature supports the potential of cyclic peptides as anticancer agents. This review summarizes the findings from previously reported studies and discusses the different cyclic peptide compounds, the sources, and their modes of action as anticancer agents. The prospects and future of cyclic peptides will also be described to give an overview on the direction of cyclic peptide development for clinical applications.